Sponsor:
Eli Lilly and Company
Code:
NCT07915245
Conditions
Obesity
Overweight
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
LY4247147
LY4247147
Placebo
Brief summary:
Conditions
Obesity
Overweight
Study ID
NCT07915245
Start date
Nov 6, 2026
Status verified date
Nov, 2026
Completion date
Oct, 2028
Anticipated
Primary completion date
Oct, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Enrollment
108 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: LY4247147 Part A
placebo comparator: Placebo Part A
experimental: LY4247147 Part B
placebo comparator: Placebo Part B
experimental: LY4247147 Part C
Interventions
LY4247147
LY4247147
Placebo
Primary outcome measure
Central contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.comLocations
ICON Early Phase Services Lenexa Center
Recruiting
Lenexa, Kansas, United States, 66219
Contacts
Principal Investigator:
DANIEL DICKERSON
Sponsor
Eli Lilly and Company
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.